10
Views
3
CrossRef citations to date
0
Altmetric
Invited Papers

Emerging Science, Emerging Ethical Issues: Who Should Fund Innate Alloimmunity-suppressing Drugs ?

, &
Pages 73-82 | Published online: 11 Mar 2016

References

  • Akira S. TLR-signaling. Curr Top Microbiol Immunol, 2006, 311: 1.
  • Munz Ch., Steinman R. M., Fujii S.-I. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Ex Med, 2005, 202: 203.
  • Jayasekera J. P., Moseman E. A., Carroll M. C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol, 2007, 81: 3487.
  • Land W. G. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation, 2005, 79: 505.
  • Mahnke K., Enk A. H. Dendritic cells: key cells for the induction of regulatory T cells ? Curr Top Microbiol Immunol, 2005, 293: 133.
  • Tan P. H., Sagoo P, Chan C. et al. Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol, 2005, 174: 7633.
  • Walsh M. C., Bourcier T., Takahashi K. et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol, 2005, 175: 541.
  • Zhang M., Austen W. G. Jr., Chiù I. et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA, 2004, 101: 3886.
  • Land W. G. Immunosuppressive strategies in organ transplantation in the light of innate immunity. Exp Clin Transplant, 2006, 4: 406.
  • Land W. G. Innate immunity mediated allograft rejection and strategies to prevent it. Transplant Proc, 2007, 39: 667.
  • Edaravone acute infarction study group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 2003, 15: 222.
  • Cao C. X., Yang Q. W., Lv F. L., et al. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Comm, 2007, 353: 509.
  • Land W., Schneeberger H., Schleibner S. et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation, 1994, 57: 211.
  • Keshavjee S., Davis R. D., Zamora M. R. et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg, 2005, 129: 423.
  • Kaden J., Strobelt V., May G. Short and long-term results after pretransplant high-dose single ATG-Fresenius bolus in cadaveric kidney transplantation. Transplant Proc, 1998, 30: 4011.
  • Tahara M., Nakayama M., Jin M. B. et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation. Transplantation, 2005, 80: 213.
  • Masini E., Cuzzocrea S., Mazzon E. et al. Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol, 2002, 136: 905.
  • Zhang X., Vladau C., Feng B. et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. WTC-Congress Boston, abstract #711. Am J Transplant (Supplement), 2006, p. 307.
  • Fire A., Xu S., Montgomery M. K. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391: 806.
  • McKay D., Shigeoka A., Rubinstein M., Surh Ch., Sprent J. Simultaneous deletion of MyD88 and Trif delays major histocom-patibility and minor antigen mismatch allograft rejection. Eur J Immunol, 2006, 36: 1994.
  • Lí M., Zhang X., Zheng X. et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells. WTC-Congress Boston, abstract# 725. Am J Transplant (Supplement), 2006, p. 311.
  • Ondiveeran H. K., Fox-Robichaud A. Drug evaluation E-5564. IDrugs, 2004, 7: 582.
  • Mahaffey K. W., van de Werf F., Shernan S. K. et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systemic overview. Am Heart J, 2006, 152: 291.
  • Trouiller P., Torreele E., Olliaro P. et al. Drugs for neglected diseases: a failure of the market and a public health failure ? Trop Med Int Health, 2001, 6: 945.
  • Wastfelt M., Fadeel B., Henter J. I. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med, 2006, 260: 1.
  • Angell M. Excess in the pharmaceutical industry. CMAJ, 2004, 171: 1451.
  • Barton J. H., Emanuel E. J. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA, 2005, 294: 2075.
  • Bobrow M., Thomas S. Patents in a genetic age. Nature, 2001, 409: 763.
  • Valverde J. L. (Ed). The European Regulation on Orphan Medicinal Products. Vol. 3: Pharmaceuticals Policy and Law. Amsterdam, The Netherlands: IOS Press, 2001.
  • Fischer A., Borensztein P., Roussel C. The European rare diseases therapeutic initiative. PLoS Med, 2005, 2: e243.
  • Brody B. A. Ethical issues in clinical trials in developing countries. Stat Med, 2002, 21: 2853.
  • Hayasaka E. Approaches vary for clinical trials in developing countries. J Natl Cancer Inst, 2005, 97: 1401.
  • Olliaro P., Smith P. G. The European and developing countries clinical trials partnership. J HIV Ther, 2004, 9: 53.
  • Wheeler C., Berkley S. Initial lessons from public-private partnerships in drug and vaccine development. Bull World Health Organ, 2001, 79: 728.
  • Demotes-Mainard J., Canet E., Segard L. Public-private partnership models in France and in Europe. Therapie, 2006, 61: 325334, 313.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.